evipedia.ai
← Back

Thymogen for Health & Longevity

Evidence Review created on 08/31/2026 using AI4L / Opus 5

Also known as: Timogen, alpha-glutamyl-tryptophan, L-glutamyl-L-tryptophan, Glu-Trp, oglufanide, oglufanide disodium, IM862

Motivation

Thymogen is a laboratory-made molecule built from just two amino acids — glutamic acid joined to tryptophan. It was originally pulled out of a natural extract of calf thymus, the small chest gland that trains the body’s immune cells, and then copied by chemical synthesis. Interest in it rests on a simple idea: if a single small fragment of thymus signalling can be given back, perhaps some of the immune capacity lost with age can be recovered.

The thymus shrinks steadily from adolescence onward, and much of the decline in immune resilience across a lifetime tracks that shrinkage. Thymogen has been a registered medicine in Russia since around 1990, sold as a nasal spray, an injection and a skin cream, while the identical molecule was developed separately in the United States under a different name and tested in cancer. The molecule therefore carries two largely separate research records.

This review examines what the published evidence shows about Thymogen — how it is thought to work, what outcomes have been measured in people and in animals, what harms have been recorded, how it is dosed, and how much weight the underlying studies can carry.

Benefits - Risks - Protocol - Conclusion

High-level sources that discuss Thymogen, or the dipeptide it consists of, in enough depth to orient a reader before the detailed evidence sections.

None of the six priority expert platforms listed in the AI4L source criteria has published anything on this compound, so no item above comes from one. Their nearest material covers thymosin alpha-1 and growth-hormone-driven thymic regrowth, which are different molecules acting by different mechanisms, and including it would have misrepresented what has been said about Thymogen.

Grokipedia

No Grokipedia article exists for Thymogen, or for its alternate identifiers alpha-glutamyl-tryptophan, oglufanide or IM862.

Examine

No Examine article exists for Thymogen.

Thymogen is a registered pharmaceutical in Russia and a handful of adjacent markets rather than a dietary supplement, and Examine.com does not typically cover medicines that have no supplement channel.

ConsumerLab

No ConsumerLab article exists for Thymogen.

Thymogen is a registered pharmaceutical rather than a dietary supplement sold in the United States retail channel, and ConsumerLab does not typically cover medicines outside that channel.

Systematic Reviews

One systematic review in the indexed literature evaluates a trial of this dipeptide; selection below was by relevance, since there is no pool large enough to rank by citation count, study size or recency.

The trade-off this compound presents is immune activation against the possibility of unwanted effects from that activation. The efficacy side is represented above; the risk side is unrepresented, because no systematic review or meta-analysis of the safety of Thymogen, alpha-glutamyl-tryptophan or oglufanide exists in PubMed. The single review above also carries a structural limitation worth naming: the IM862 trials it pools were sponsored by the compound’s developers, so the evidence base on both sides of this section originates largely with parties holding a commercial interest in the result.

Mechanism of Action

Thymogen is the alpha-linked dipeptide L-glutamyl-L-tryptophan. It was isolated from the calf-thymus complex Thymalin by high-performance liquid chromatography (HPLC — a laboratory method that separates a mixture into its components), then produced synthetically.

Its developers call it a signalling fragment, not a hormone. Reported actions include accelerated T-cell differentiation, improved recognition of peptide–MHC complexes (major histocompatibility complex — cell-surface proteins that display protein fragments to immune cells), shifts in intracellular cyclic nucleotides, and increased neutrophil chemotaxis and phagocytosis (movement toward, and engulfment of, microbes). In cultured endothelial and mononuclear cells it lowered TNF-α-driven IL-1α and IL-8 while raising ICAM-1 (tumour necrosis factor alpha and the interleukins are inflammatory signalling proteins; intercellular adhesion molecule 1 helps immune cells cross vessel walls).

A competing account came from the Western programme, which pursued it as a blocker of VEGF (vascular endothelial growth factor — the main signal for new blood vessels). Its antitumour effect in mice required natural killer cells and perforin, was partly interleukin-12-dependent and interferon-gamma-independent. A third account, from the chemists who made both mirror images: the stereochemistry itself sets the direction: the L,L-form stimulates, the D,D-form suppresses.

It is a 333-dalton dipeptide with no identified receptor and no selectivity. It is not a cytochrome P450 substrate (the liver enzyme family that clears most drugs); aminopeptidases hydrolyse it to glutamate and tryptophan, giving a plasma half-life of minutes. Poor intestinal permeability is why intranasal and intramuscular routes are used. Tissue distribution has not been mapped in humans.

Historical Context & Evolution

Thymogen originates in Soviet military medicine. Vladimir Khavinson and Vyacheslav Morozov, working at the Military Medical Academy in Leningrad, extracted a peptide complex from calf thymus and registered it as Thymalin to correct immune suppression in irradiated and injured personnel. Fractionating that complex identified one active dipeptide, which was synthesised and registered as Thymogen around 1990. Its original indication was secondary immunodeficiency (depressed immune function caused by illness, injury, surgery or toxic exposure rather than by an inherited defect).

The longevity interest is traceable to a specific finding rather than to theory. Twelve months of dosing in rats produced a longer maximum lifespan, a modelled aging rate roughly 40% lower, and total tumour incidence 1.5 times lower than controls. A companion experiment reported suppression of strontium-90 and caesium-137-induced carcinogenesis.

In parallel and apparently independently, Cytran Inc. in Washington State developed the identical dipeptide as oglufanide disodium, or IM862, on a wholly different rationale: starving tumours of blood supply. That programme reached a 202-patient phase III trial in AIDS-related Kaposi sarcoma, and failed.

The phase III failure is often cited as having settled the matter. That reading needs care. The trial tested one dose, one route and one disease, and its own investigators attributed much of the response seen in both arms to antiretroviral therapy. It refutes an anti-angiogenic cancer claim; it does not test the immunological claims Russian practice rests on, which remain untested by any Western-standard trial in either direction.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no clinical endpoint has been reproduced in more than one controlled human trial — the only placebo-controlled endpoint data come from a single gastritis trial programme, and the one placebo-controlled oncology trial was negative on its primary outcome.

Medium 🟩 🟩

Regeneration of Atrophic Gastric Mucosa

Alpha-glutamyl-tryptophan is registered in Russia as a mucosal repair agent. In a multicentre double-blind randomized controlled trial of 116 patients with Helicobacter pylori-associated atrophic gastritis (thinning of the stomach lining caused by a common stomach bacterium), gland density rose against placebo and CDX-2 rose from baseline (CDX-2 is a gene marker of intestinal-type cell identity used here as a repair signal). A companion analysis of 80 of those patients found less mucosal oedema and fewer inflammatory cells. Both reports come from one trial programme run by the manufacturer’s collaborators.

Magnitude: Gland density per mm² of gastric mucosa rose 26.1% from baseline (p=0.028; p is the probability a result this large would arise by chance alone) and differed from placebo (p=0.026); mucosal oedema scores fell (p=0.008) and total acute-inflammation scores fell (p=0.006).

Low 🟩

Prophylaxis of Acute Respiratory Infections

Intranasal and subcutaneous Thymogen was given to conscripts in a Soviet military training unit, and the report describes lower incidence, severity and duration of influenza and other acute respiratory infections. The design was an open epidemiological comparison without blinding, and no numerical effect estimates were published.

Magnitude: Direction is consistent — lower incidence, severity and duration of influenza and other acute respiratory infections — and it holds for both intranasal and subcutaneous dosing in a military training unit; the only published report, a 1993 Russian-language field summary, gives no incidence rate or comparative statistic, so the literature reports no outcome figure.

Correction of Depressed T-Cell Immunity in Secondary Immunodeficiency

Uncontrolled Russian series in type 1 diabetes and in complicated gallstone disease report normalised T-lymphocyte subsets and fewer postoperative complications after Thymogen. Both were open-label, single-centre, and scored success on measures the investigators chose themselves, so improvement that would have happened anyway and patient expectation cannot be excluded.

Magnitude: In the diabetes series a clinical effect was recorded in 94.4% and a laboratory effect in 83.3% of treated patients; with no control group these are response proportions, not treatment effects.

Antitumour Activity in Kaposi Sarcoma ⚠️ Conflicted

An open randomized phase II study of intranasal IM862 in AIDS-related Kaposi sarcoma reported 36% major responses. The subsequent placebo-controlled phase III found no difference. Net reading: the apparent activity was attributable to concurrent antiretroviral therapy, not to the peptide.

Magnitude: Phase II major response 36% (16 of 44, uncontrolled); phase III response 23% (95% CI 15–32%) with IM862 versus 21% (95% CI 14–31%) with placebo, p=0.46 (CI is the confidence interval, the range in which the true value most likely lies).

Speculative 🟨

Delayed Aging Rate and Lower Tumour Incidence in Rodents

In female rats dosed for twelve months, maximum lifespan lengthened and the modelled aging rate fell by roughly 40%, with fewer radiation-induced tumours in a companion study. No human lifespan data exist.

Suppression of Circulating Vascular Endothelial Growth Factor

In a 25-patient renal-cell carcinoma (kidney cancer) phase II trial, plasma VEGF fell significantly at four and eight weeks without any objective tumour response. VEGF is an unvalidated surrogate here.

Liver-Cell Repair and Antioxidant Defence

Rat models of carbon-tetrachloride and hydrazine liver injury show restored catalase activity (an enzyme that clears hydrogen peroxide) and reduced fat-oxidation markers, with C-terminal D-alanine analogues outperforming Thymogen itself. No human liver-outcome data exist.

Stimulation of Skin Repair-Cell Renewal

In cultured human skin fibroblasts (skin repair cells), Glu-Trp raised a cell-division marker and lowered a cell-death enzyme, matching a reference wound agent. This is a cell-culture assay with no controlled human wound-healing outcome.

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic marker has been validated. Candidate modifiers are variants in PEPT1 (peptide transporter 1, which carries dipeptides across cell membranes) and in aminopeptidase genes governing how fast the molecule is cleaved, but neither has been studied.

  • Baseline biomarker levels: Every reported clinical effect comes from cohorts selected for documented immune depression — low lymphocyte counts, reduced T-cell subsets, or active mucosal inflammation. In people whose baseline markers sit in range, no study has demonstrated headroom for benefit.

  • Sex-based differences: Untested. The two Kaposi sarcoma trials enrolled almost exclusively men; the rodent lifespan work used only females; the gastritis trial did not stratify by sex. No sex-specific dose or response has been described.

  • Pre-existing health conditions: Helicobacter pylori status appears to matter for the gastric endpoint, since the trial required it. Active viral infection was the setting for most Russian claims. Established malignancy is where the one controlled trial found harm rather than benefit.

  • Age-related considerations: Thymic output falls steeply after adolescence, so the theoretical case is strongest for older adults. No trial has stratified by age, and adults over 65 are essentially absent from the published cohorts, leaving the age at which the case is strongest untested.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mild Transient Adverse Events

Across the two Western oncology programmes using this dipeptide, treatment-related events were limited to mild, self-limiting headache, fatigue, paraesthesia (tingling or pins-and-needles) and nausea. No haematological toxicity was attributed to the drug in the 44-patient Kaposi sarcoma study, and no grade 2 or grade 3 toxicity was recorded in the 25-patient renal-cell carcinoma study. The approved Russian labelling adds one local reaction, allergic rhinitis, for the nasal spray, and names two contraindications — hypersensitivity and age under one year.

Magnitude: Direction is consistent — every attributed event was mild and reversible — and it holds across intranasal doses from 5 mg every other day to 20 mg three times daily; neither trial reports per-event incidence and the labelling gives no frequency for allergic rhinitis, so the literature gives no outcome figure. The only labelled overdose effect is profuse nasal secretion, which stops on withdrawal.

Medium 🟥 🟥

Accelerated Disease Progression in Kaposi Sarcoma

In the 202-patient double-blind phase III trial, patients receiving intranasal IM862 progressed sooner than those receiving placebo. The investigators proposed that the peptide may interfere with the tumour regression driven by antiretroviral therapy, since outcomes in the placebo arm tracked immune reconstitution. This is the only randomized signal of net harm for the molecule; it comes from a single trial in one disease and has been neither reproduced nor refuted.

Magnitude: Median time to progression 16 weeks (95% CI 13–27) with IM862 versus 35 weeks (95% CI 26–114) with placebo, p=0.012.

Low 🟥

Theoretical Autoimmune Activation

The mirror-image D-enantiomer of this dipeptide is registered in Russia as an immunosuppressant for autoimmune disease, which implies the L-form pushes T-cell activity the other way. No autoimmune flare has been reported in published human use, so the concern remains inferential rather than observed.

Magnitude: Not quantified in available studies. No controlled trial has enrolled patients with active autoimmune disease, and the Russian clinical literature does not capture autoimmune adverse events as a defined endpoint.

Speculative 🟨

Antiproliferative Effect at High Concentrations

Concentrations of 10–1000 µg/mL suppressed proliferation of cultured human lymphocytes, while 0.001–1 µg/mL did not and reduced chemically induced chromosome damage. Cell-culture data only; tissue concentrations from labelled dosing are far lower.

Isomer-Dependent Suppression of Blood-Forming Stem Cells

In mice, D-glutamate-containing isomers of Glu-Trp inhibited spleen colony-forming units while the L,L-form was inert, so stereochemical impurity in an unregulated product could produce the opposite of the intended effect. Rodent assay only.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant has been shown to modify risk. Rapid-hydrolysis phenotypes driven by aminopeptidase variants would shorten exposure rather than raise it, so the theoretical direction is toward less effect, not more toxicity.

  • Baseline biomarker levels: A raised antinuclear antibody titre (antibodies targeting the cell nucleus, typical of autoimmune disease) or an unexplained rise in lymphocyte count marks where immune activation has the largest theoretical downside. Neither is validated as a risk marker.

  • Sex-based differences: No sex-specific adverse-event pattern has been reported. The Kaposi sarcoma trials were 95% male and the renal-cell trial predominantly male, so any female-specific signal would not have been detectable.

  • Pre-existing health conditions: Active malignancy is the one condition in which controlled data show harm. Solid-organ transplantation and systemic autoimmune disease are the conditions in which the drug’s own pharmacology argues against use.

  • Age-related considerations: Adults over 65 carry more autoimmune serology and more undiagnosed malignancy, both of which raise the theoretical downside. The published cohorts contain too few older adults to detect any age-related difference in tolerability.

Key Interactions & Contraindications

  • Systemic immunosuppressants (ciclosporin, tacrolimus, mycophenolate, sirolimus): Absolute contraindication in transplant recipients. Direct pharmacodynamic opposition; the clinical consequence is loss of graft protection. No mitigation exists other than avoidance.

  • Systemic corticosteroids (prednisone, dexamethasone, methylprednisolone): Caution. Opposing effects on T-cell activation may blunt either agent. If both are unavoidable, the corticosteroid indication takes precedence and the peptide is stopped rather than dose-adjusted.

  • Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab): Caution, with oncology supervision. These cancer drugs release the brakes on T cells, so additive activation raises the theoretical risk of immune-related adverse events. Mitigation is to separate courses entirely rather than overlap them.

  • Cytotoxic chemotherapy and systemic antibacterials (fluorouracil, irinotecan, doxycycline) and radiotherapy: Monitor. Russian labelling states the peptide increases their efficacy, so toxicity may rise alongside it. Mitigation is oncologist-supervised dosing rather than independent addition to an active treatment schedule.

  • Antiretroviral therapy: Monitor. No pharmacokinetic interaction is expected, but the phase III Kaposi sarcoma trial suggests the peptide may work against antiretroviral-driven tumour regression. Mitigation is to avoid the combination while lesions are still regressing.

  • Over-the-counter intranasal decongestants (oxymetazoline, xylometazoline, phenylephrine): Caution with the nasal spray only. Mucosal vasoconstriction may reduce absorption. No interaction appears in the Russian labelling; separating administration by at least two hours is the pragmatic mitigation.

  • Over-the-counter antihistamines and non-steroidal anti-inflammatory drugs (cetirizine, ibuprofen, naproxen): No documented interaction; listed because they are the commonest self-treatment during the respiratory-infection indication. Monitor only; no timing separation or dose change is described.

  • Immunostimulant supplements with additive effects (echinacea, beta-glucans, AHCC (active hexose correlated compound, a mushroom extract), bovine colostrum, thymus glandular extracts): Caution. These push the same direction, so combined use compounds the autoimmune-activation concern without added evidence. Mitigation is one immunomodulator at a time.

  • Thymosin alpha-1 and thymopentin: Caution. Different molecules with the same intent; stacking them offers no documented additive benefit and doubles the theoretical activation risk. Mitigation is sequential rather than concurrent courses.

  • Zinc, vitamin D and selenium: Monitor. Additive T-cell stimulation on top of a deficiency correction is the consequence, which compounds the autoimmune-activation concern. Assessing and repleting these before a course, not alongside one, is the mitigation.

  • Other interventions — live attenuated vaccines (measles-mumps-rubella, varicella-zoster, yellow fever): Caution. The consequence would be a stronger-than-usual vaccine reaction or a weaker response to it, neither studied with this peptide. Separating a course from live vaccination by two weeks is the mitigation.

Populations who should avoid Thymogen:

  • Solid-organ or haematopoietic stem-cell transplant recipients on maintenance immunosuppression, at any time post-transplant

  • People with active systemic autoimmune disease requiring systemic therapy — including systemic lupus erythematosus, rheumatoid arthritis with a Disease Activity Score above 3.2, and Graves’ disease

  • People with an active vascular tumour, and specifically anyone with AIDS-related Kaposi sarcoma within the first 6 months of antiretroviral therapy, when regression is still ongoing

  • Pregnant or breastfeeding women, on the basis that no reproductive toxicology has been published

  • People with documented hypersensitivity to the peptide or to benzalkonium chloride, the preservative in the metered nasal spray

  • Children under 1 year, which is the lower age limit stated in the Russian labelling for the nasal spray; reduced schedules apply from 1 to 6 and from 7 to 14 years

Risk Mitigation Strategies

  • Baseline autoimmune serology before the first course: An antinuclear antibody titre and thyroid antibodies taken at baseline identify the subgroup in whom immune activation carries the largest theoretical downside, mitigating the autoimmune-flare risk.

  • Exclusion of active malignancy before starting: Age-appropriate cancer screening completed within 12 months mitigates the one risk with randomized human evidence behind it — accelerated progression of an existing vascular tumour.

  • Labelled course length rather than continuous dosing: Russian labelling caps a therapeutic course at 10 days and a prophylactic course at 3–5 days; staying inside those limits avoids open-ended exposure that no study has characterised.

  • Intranasal presentation first: Establishing tolerance on the 25 µg metered spray before any injected route mitigates injection-site reactions and puts a systemic hypersensitivity reaction on the slower mucosal absorption curve rather than a bolus.

  • Stereochemistry verification on any non-pharmacy material: A certificate of analysis confirming the L,L-configuration and alpha-linkage mitigates the isomer risk, since D-glutamate-containing isomers suppress blood-forming stem cells in rodents.

  • Separation from any concurrent immunomodulator: Running one immune-active agent at a time, with at least two weeks between courses, mitigates compounded activation from stacked supplements, thymic peptides or checkpoint inhibitors.

  • Lymphocyte subset recheck after two courses: A complete blood count with differential and a CD4:CD8 ratio (the balance between two T-cell types) repeated at 8–12 weeks detects unexpected lymphocyte suppression before further courses.

Therapeutic Protocol

  • Standard registered regimen: Russian labelling defines the protocol; there is no Western prescribing standard, since the compound has never been approved outside the Commonwealth of Independent States and a small number of adjacent markets.

  • Intranasal course: 25 µg per metered dose, one spray into each nostril twice daily. Ten days for a therapeutic course; 3–5 days for prophylaxis during a respiratory-infection season.

  • Intramuscular course: 100 µg/mL solution, 100 µg once daily for 3–10 days, reserved in Russian practice for documented secondary immunodeficiency rather than for general use.

  • Topical presentation: 0.05% cream applied to the affected area, used for wound and skin repair indications and not interchangeable with the systemic routes.

  • Competing therapeutic approaches: The Russian protocol treats it as a short immune-correcting course. The Western programme dosed it continuously at 5–20 mg intranasally as an anti-angiogenic. Neither has outperformed the other on any shared endpoint.

  • Who popularised each approach: The course-based immunological protocol comes from Khavinson and Morozov’s St Petersburg Institute of Bioregulation and Gerontology and the manufacturer Cytomed; the continuous anti-angiogenic schedule came from Cytran Inc. and the AIDS Malignancy Consortium.

  • Best time of day: Morning dosing is conventional in Russian practice. No study of time-of-day dosing exists; the rationale offered is alignment with the morning peak in circulating lymphocyte trafficking.

  • Half-life: Minutes. Aminopeptidases hydrolyse the dipeptide rapidly, so systemic exposure is a brief pulse rather than a sustained level — the reason courses are repeated daily rather than dosed to steady state.

  • Single versus split dosing: The nasal spray is split into two daily administrations precisely because of that short half-life; the intramuscular presentation is given as a single daily dose, reflecting depot-like absorption from muscle rather than any measured advantage.

  • Genetic polymorphisms influencing dose: None validated. No pharmacogenetic testing informs dosing, and no variant in PEPT1, aminopeptidase or tryptophan-metabolism genes has been examined against response.

  • Sex-based differences in dosing: None described. The Russian labelling gives one adult dose regardless of sex, and no trial has compared response between men and women.

  • Age-related considerations: The labelling contraindicates the nasal spray under 1 year and runs a reduced paediatric schedule to 14 years, but sets no upper limit and no reduction for older adults despite routinely reduced renal and hepatic clearance.

  • Baseline biomarker levels influencing response: Russian protocols select patients with laboratory-confirmed immune depression. Where lymphocyte subsets are normal at baseline, no protocol adjustment is described and no response has been demonstrated.

  • Pre-existing conditions influencing response: Confirmed Helicobacter pylori infection defined eligibility in the one placebo-controlled trial with a positive result, so the gastric protocol assumes eradication therapy alongside rather than instead of it.

Discontinuation & Cycling

  • Intended duration: Short-term by design. Every registered protocol is a defined course of 3–10 days, not continuous therapy; no labelling and no trial supports indefinite use.

  • Withdrawal effects: None documented. No withdrawal syndrome, rebound immune suppression or dependence has been reported in the trial literature or in Russian post-marketing summaries.

  • Tapering: Not applicable. Courses are stopped abruptly at the end of the scheduled days, and no tapering schedule appears in any labelling or protocol.

  • Cycling: Cycling is the standard, not an optimisation. Russian practice repeats a 10-day course after an interval of one to six months, with the interval chosen by indication rather than by any efficacy-retention data.

  • Rationale for the intervals: No study has compared course intervals or tested whether repeated courses lose effect. The interval convention is regulatory and empirical, and the evidence to refine it does not exist.

Sourcing and Quality

  • Regulatory source: The only pharmaceutical-grade supply is the registered Russian product from Cytomed, available through pharmacies in Russia and several adjacent markets. It has no marketing authorisation in the United States, the European Union, the United Kingdom or Canada.

  • Name collision to check first: Products marketed as “Thymogen Alpha 1” are thymosin alpha-1 preparations, a 28-amino-acid peptide that is a different molecule entirely. Verifying that a label states glutamyl-tryptophan is the first sourcing step.

  • Stereochemistry and linkage: A certificate of analysis should confirm the L,L-configuration and the alpha-glutamyl linkage. The D,D-isomer is a registered immunosuppressant, and gamma-linked variants behave differently in blood-forming assays.

  • Purity specifications to look for: HPLC purity of at least 98%, mass-spectrometric confirmation of the 333-dalton mass, water content below 8%, and bacterial endotoxin testing for any material intended for injection.

  • Third-party testing: No independent certification programme covers this compound. Grey-market “research chemical” vendors are not subject to any supplement-industry testing scheme, so an independent laboratory assay is the only verification available.

  • Compounding pharmacies: United States compounding pharmacies cannot lawfully compound it, since it is not an approved drug and does not appear on the FDA (Food and Drug Administration) bulk drug substances list. Legitimate compounded supply does not exist in that market.

Practical Considerations

  • Time to effect: The gastritis trial measured its histological endpoint after a full treatment course and re-biopsy, on a timescale of weeks to months. Respiratory-infection reports describe effects within a single 3–10 day course.

  • Common pitfall — confusing the molecules: The most frequent error is buying thymosin alpha-1 sold under a similar trade name and attributing this compound’s evidence to it, or the reverse. The two share neither structure nor evidence base.

  • Common pitfall — extrapolating rodent lifespan data: The rat aging results are the single most-quoted finding and the least transferable, since no human lifespan, mortality or healthspan endpoint has ever been measured for this dipeptide.

  • Common pitfall — continuous dosing: Users who dose daily for months are outside every studied protocol. The registered schedules are short courses with long intervals, and the safety record applies only to that pattern.

  • Regulatory status: Unapproved in all major Western markets, making any use there an unapproved new drug rather than an off-label one. Importation for personal use sits in a legally uncertain category in the United States and the European Union.

  • Cost and accessibility: In Russia the nasal spray is inexpensive and pharmacy-available. Outside those markets access is limited to grey-market vendors, which is an accessibility barrier and a quality risk rather than a price barrier.

  • Payer incentives: Thymosin alpha-1 costs far more per course than this dipeptide, so national health systems where both are sold have a structural incentive to favour the cheaper agent — a bias to weigh when reading Russian guideline literature.

Interaction with Foundational Habits

  • Sleep: No direct interaction is documented, and the short half-life makes an overnight effect unlikely. The indirect link runs the other way: slow-wave sleep drives much of the T-cell priming this peptide targets, so short sleep plausibly blunts any response. Morning dosing avoids the theoretical stimulation concern.

  • Nutrition: Indirect and potentially confounding. The molecule is hydrolysed to glutamate and tryptophan, both abundant in ordinary protein intake, so the dose contributes nothing nutritionally. Zinc, selenium and vitamin D deficiency each depress T-cell function; correcting them first avoids attributing a nutritional repair to the peptide.

  • Exercise: No documented interaction, blunting or potentiation. Prolonged high-volume endurance training transiently suppresses mucosal immunity, which is the state the respiratory-infection protocol targets, so any benefit is likeliest around heavy training blocks. No timing relationship to workouts has been studied.

  • Stress management: Indirect and opposing. Sustained cortisol elevation suppresses T-cell differentiation through the same pathway the peptide is proposed to stimulate, so chronic psychological stress works against it. No cortisol or stress-response measurement has been reported in any trial of this compound.

Monitoring Protocol & Defining Success

Baseline testing before a first course establishes whether the immune deficit the peptide targets is actually present, since every reported clinical effect comes from cohorts selected for measurable immune depression. A reasonable baseline panel covers lymphocyte quantity and subsets, general inflammation, antibody classes, autoimmune serology and liver enzymes, plus age-appropriate cancer screening completed within the preceding twelve months.

Ongoing monitoring follows the course structure rather than a continuous schedule: the lymphocyte panel and inflammation marker are repeated at 8–12 weeks, which is after roughly two courses, then every 6–12 months while courses continue. Autoimmune serology is repeated only if new joint, skin or systemic symptoms appear. Where a gastric indication is the reason for use, re-biopsy is timed to the treating gastroenterologist’s schedule rather than to the peptide course.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Absolute lymphocyte count 1.8–3.0 ×10⁹/L Confirms the immune deficit the peptide is meant to correct Part of a CBC (complete blood count) with differential; no fasting required
CD4+ T-cell count 700–1,400 cells/µL Direct read-out of the T-cell compartment the peptide targets CD4 is a surface marker on helper T cells; best drawn at a consistent time of day, as counts vary through the day
CD4:CD8 ratio 1.5–2.5 A ratio below 1.0 marks immune aging independently of absolute counts Conventional laboratories often report only “greater than 1.0” as normal, which misses early drift
hs-CRP Below 1.0 mg/L Tracks the anti-inflammatory claim made for the compound hs-CRP is high-sensitivity C-reactive protein, a general inflammation marker; conventional cut-off is below 3.0 mg/L; testing is deferred until 2 weeks after any infection
Immunoglobulins IgG, IgA, IgM IgG 700–1,600 mg/dL; IgA 70–400 mg/dL; IgM 40–230 mg/dL Separates antibody deficiency from T-cell deficiency before attributing symptoms Immunoglobulins are antibodies; short peptide courses are not expected to move them, so a change suggests another cause
Antinuclear antibody titre Below 1:40 Screens for the theoretical autoimmune-activation risk Antinuclear antibodies target the cell nucleus; paired with thyroid antibodies at baseline; best drawn at the same visit as the lymphocyte panel
ALT and AST ALT 10–26 U/L (men), 8–22 U/L (women) Baseline liver panel, since the animal repair data are hepatic ALT and AST are liver enzymes; conventional upper limits near 40 U/L are considerably looser than the functional range; fasting preferred
Gastric histology, OLGA stage No established target; track the change from the individual’s own staged baseline The only endpoint with placebo-controlled human data behind it OLGA is the Operative Link on Gastritis Assessment, a staging system for how much stomach lining has thinned; applies only when a gastric indication is the reason for use
Plasma VEGF No established target; track direction against the individual’s own baseline The one biomarker that moved in a controlled Western trial Rarely offered outside research laboratories, requires a consistent collection tube, and is not validated as an outcome surrogate

Qualitative markers worth tracking alongside the laboratory panel:

  • Frequency and duration of upper respiratory infections across a season, compared with the individual’s own prior seasons

  • Time to recover from ordinary infections, measured as days to return to normal activity

  • Wound and skin healing speed, which is the endpoint the topical presentation targets

  • Energy levels and post-exertional recovery, which decline early when immune load is high

  • Upper gastrointestinal symptoms — fullness, early satiety, discomfort after meals — where a gastric indication applies

Emerging Research

  • No active trial exists: A ClinicalTrials.gov search on 2026-08-31 returns three registered records for this dipeptide, all closed, and none recruiting. The registry pipeline for this compound is empty in every jurisdiction that reports to it.

  • Phase III in Kaposi sarcoma, completed: NCT00002445, sponsored by Cytran, randomized 200 participants to intranasal IM862 or placebo with tumour response as the primary endpoint. Published as negative, and it remains the largest controlled test of the molecule.

  • Phase I dose escalation in ovarian cancer, completed: NCT00003773, 43 participants at the University of Southern California with National Cancer Institute support, seeking a maximum tolerated dose and tracking VEGF. Results were never published, leaving the dose ceiling unreported.

  • Phase II with chemotherapy in colorectal cancer, terminated: NCT00006037 enrolled 18 of a planned 66 and stopped for the stated reason “drug not available”. Commercial withdrawal, not a safety or futility finding, ended this line of investigation.

  • Enantiomer pharmacology could strengthen the case: Deigin et al., 2024 argue that the L- and D-forms are a matched pair of opposing immune drugs. If that holds, it supplies the mechanistic rationale the immunological claims have always lacked.

  • Structural analogues may supersede the parent compound: Chulanova et al., 2025 found that D-alanine-extended analogues outperformed Thymogen itself in rat liver injury, with the C-terminal variant strongest. Success here would redirect development away from the original dipeptide rather than validate it.

  • Independent replication could weaken the case: Khedr et al., 2021 found the anti-angiogenic effect real but weaker than an unrelated dipeptide tested alongside it. Further independent screening on that pattern would erode the original antitumour rationale.

  • Whether gastric histology translates to outcomes: The gastritis trial of Baryshnikova et al., 2023 measured gland density, not cancer incidence. A long-term follow-up cohort would decide whether the one positive controlled result carries clinical weight or none.

Conclusion

Thymogen is a two-amino-acid molecule taken from an extract of calf thymus and then made synthetically, sold in Russia for more than three decades as a short course of nasal spray, injection or cream to correct weakened immune defences. The same molecule was developed separately in the United States as a cancer drug aimed at starving tumours of blood supply.

The evidence sits at two extremes and almost nothing in between. On one side, a placebo-controlled trial in stomach-lining thinning found a real repair effect, and rodent work reports longer maximum lifespan and fewer tumours. On the other, the largest controlled trial ever run on the molecule found no benefit in a blood-vessel cancer and a signal that treated patients worsened sooner than untreated ones. Most of the remaining human material is Russian reports on treated patients only, with no comparison group and no published numbers.

Side effects look mild: brief headache, tiredness, tingling and nausea, plus nose irritation from the spray, with no organ or blood damage recorded. That reassurance is real but narrow, since it comes from short courses in a few hundred people.

Two features shape how much weight this evidence carries. Almost all of it was produced by the compound’s own developers and manufacturer on both continents. And the immunological claims that Russian practice rests on have never been tested to Western trial standards — neither confirmed nor ruled out.

Top - Benefits - Risks - Protocol